What is Dianthus Therapeutics Inc.?
, a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.76B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 17167,166 shares $15.7M | 0 |
| 3-6months | 319,342 shares $2.2M | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |